Danaher Co. (NYSE:DHR) Shares Acquired by Stokes Family Office LLC

Stokes Family Office LLC boosted its position in Danaher Co. (NYSE:DHR) by 8.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 2,225 shares of the conglomerate’s stock after acquiring an additional 165 shares during the quarter. Stokes Family Office LLC’s holdings in Danaher were worth $515,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in DHR. BKM Wealth Management LLC acquired a new stake in Danaher in the fourth quarter valued at about $27,000. Wetzel Investment Advisors Inc. acquired a new stake in Danaher in the fourth quarter valued at about $29,000. OFI Invest Asset Management acquired a new stake in Danaher in the third quarter valued at about $30,000. Rakuten Securities Inc. purchased a new position in Danaher in the fourth quarter valued at about $36,000. Finally, Financial Connections Group Inc. purchased a new position in Danaher in the fourth quarter valued at about $41,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DHR. Barclays increased their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a report on Wednesday, April 24th. Robert W. Baird raised their price objective on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Citigroup raised their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Royal Bank of Canada raised their price objective on shares of Danaher from $254.00 to $282.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Insider Transactions at Danaher

In other news, Director Teri List sold 3,289 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the sale, the director now owns 19,726 shares of the company’s stock, valued at $4,898,360.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Alan G. Spoon sold 708 shares of the stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Teri List sold 3,289 shares of the stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total value of $816,724.48. Following the completion of the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The disclosure for this sale can be found here. Insiders sold 107,273 shares of company stock valued at $26,813,819 over the last quarter. Company insiders own 11.10% of the company’s stock.

Danaher Trading Up 0.6 %

NYSE:DHR traded up $1.54 on Friday, hitting $248.38. 1,787,817 shares of the stock were exchanged, compared to its average volume of 2,914,990. The stock has a market cap of $183.97 billion, a PE ratio of 42.10, a PEG ratio of 3.80 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31. The stock has a fifty day moving average of $248.59 and a 200-day moving average of $232.00.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. During the same period in the previous year, the company posted $2.36 earnings per share. Danaher’s revenue was down 2.6% compared to the same quarter last year. As a group, equities analysts expect that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were given a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.43%. Danaher’s dividend payout ratio is presently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.